Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-430-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees44
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions
What is Stoke Therapeutics' stock symbol?
Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."
How were Stoke Therapeutics' earnings last quarter?
Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.58. View Stoke Therapeutics' Earnings History.
When is Stoke Therapeutics' next earnings date?
What price target have analysts set for STOK?
4 brokers have issued 12-month target prices for Stoke Therapeutics' stock. Their forecasts range from $34.00 to $44.00. On average, they expect Stoke Therapeutics' share price to reach $37.6667 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Price Targets for Stoke Therapeutics.
What is the consensus analysts' recommendation for Stoke Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stoke Therapeutics.
Has Stoke Therapeutics been receiving favorable news coverage?
Media stories about STOK stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Stoke Therapeutics earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Stoke Therapeutics.
Who are some of Stoke Therapeutics' key competitors?
Some companies that are related to Stoke Therapeutics include FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Arena Pharmaceuticals (ARNA) and PTC Therapeutics (PTCT).
What other stocks do shareholders of Stoke Therapeutics own?
Who are Stoke Therapeutics' key executives?
Stoke Therapeutics' management team includes the folowing people:
- Dr. Edward M. Kaye, CEO & Director (Age 70)
- Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
- Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
- Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
- Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)
When did Stoke Therapeutics IPO?
(STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.
When did Stoke Therapeutics' quiet period expire?
Stoke Therapeutics' quiet period expired on Monday, July 29th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. During Stoke Therapeutics' quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Who are Stoke Therapeutics' major shareholders?
Stoke Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Cormorant Asset Management LP (5.94%), Perceptive Advisors LLC (2.14%), Janus Henderson Group PLC (1.27%), Janus Henderson Group PLC (1.27%), Price T Rowe Associates Inc. MD (1.20%) and Orbimed Advisors LLC (0.41%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Institutional Ownership Trends for Stoke Therapeutics.
Which major investors are buying Stoke Therapeutics stock?
STOK stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Perceptive Advisors LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Price T Rowe Associates Inc. MD, Orbimed Advisors LLC, Vanguard Group Inc. and Citadel Advisors LLC. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP and Rtw Investments, Lp. View Insider Buying and Selling for Stoke Therapeutics.
How do I buy shares of Stoke Therapeutics?
Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stoke Therapeutics' stock price today?
One share of STOK stock can currently be purchased for approximately $30.87.
How big of a company is Stoke Therapeutics?
What is Stoke Therapeutics' official website?
How can I contact Stoke Therapeutics?
Stoke Therapeutics' mailing address is 3 PRESTON COURT, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]
MarketBeat Community Rating for Stoke Therapeutics (NASDAQ STOK)
MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote "Outperform" if you believe STOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
